Davita Inc.

DaVita Inc., a for-profit healthcare organization headquartered in Denver, Colorado, delivers dialysis and renal care services to the federal government as a prime contractor (99% of recent awards) on an unrestricted, full-and-open basis across the Department of Veterans Affairs system and the Department of Defense. The company operates through more than 2,700 subsidiaries including Total Renal Care Inc., Renal Treatment Centers (California, Mid-Atlantic, West, and Southeast regional divisions), and DVA Healthcare Renal Care Inc., which collectively manage large-scale dialysis programs across multiple VA Integrated Service Networks and Defense Health Agency facilities.

DaVita's federal footprint concentrates almost entirely on the Department of Veterans Affairs. The top five customer entities account for 71% of recent awards by count but drive 100% of combined potential value. VA Veterans Integrated Service Network 19 leads by dollar magnitude (21 awards, $9.89 billion combined potential value), followed by VA Headquarters (17 awards, $5.96 billion), VA Veterans Integrated Service Network 8 (4 awards, $3.81 billion), the Veterans Health Administration broadly (2 awards, $142 million), and VA VISN 21 (23 awards, $22.9 million). This concentration in VISN 19 and Headquarters reflects DaVita's role as the primary national dialysis service provider across the VA system. Across 129 total federal awards since May 2000, DaVita has accrued $19.84 billion in combined potential value, with $3.24 billion obligated to date (16% utilization).

DaVita's capability portfolio centers on kidney dialysis and renal replacement therapies. Concrete services include acute inpatient dialysis, outpatient hemodialysis, peritoneal dialysis, continuous renal replacement therapy (CRRT), and therapeutic apheresis treatments delivered at VA medical centers nationwide. Representative awards illustrate the scale and scope: a $2.6 billion multiple-award National Dialysis Service Contract (NDSC) with VA Headquarters (May 13, 2026, performance through September 30, 2031) serves as the parent vehicle for numerous task orders; a $1.197 billion single-award National Dialysis Service Contract with VA Headquarters (October 1, 2025, through September 30, 2026) generated fourteen monthly or quarterly express-report delivery orders ranging from $11.3 million to $205.9 million per order in fiscal year 2025; a $1.091 billion National Dialysis Service Contract Bridge (October 1, 2024, through September 30, 2025) issued eleven delivery orders; and a $1.375 million single-award indefinite-delivery contract with VA VISN 20 (June 1, 2026, through May 31, 2031) covers acute bedside dialysis for approximately 125 admitted inpatients at facilities in Boise, Idaho, with a guaranteed minimum of 200 units and maximum of 2,000 units across the contract period. NAICS coding confirms the specialization: 125 of 127 coded awards fall under NAICS 621492 (Kidney Dialysis Centers), with 78 awards in PSC Medical-Other and 25 in PSC Medical-Nursing.

DaVita's vehicle position anchors to five primary IDVs. The Indefinite Delivery Contract VA79113D0013 carries 18 task orders totaling $7.15 billion in combined potential value. The National Dialysis Service Contract Bridge (36C10G24D0093) generated 11 task orders with $590.7 million combined potential value. VA VISN 21's inpatient dialysis services contract (36C26119D0058) issued 6 task orders for $7.2 million. The VA Central California Healthcare System inpatient dialysis contract (36C26020D0007) supports 6 task orders valued at $1.2 million. Regional contracts across VISN 15, VISN 20, and VISN 8 complete the portfolio.

Activity has accelerated recently. The award trajectory shows 6 awards in 2022, 5 in 2023, 7 in 2024, 14 in 2025, and 5 in the first six weeks of 2026 — indicating consistent quarterly and monthly task-order issuance under standing NDSC vehicles rather than discrete project wins. Only 3 awards (combined potential value $4.7 million) face ultimate completion within the next twenty-four months, reflecting the multi-year nature of the national dialysis contracts and minimal near-term recompete exposure in the source snapshot. Most awards are monthly or quarterly express-report delivery orders under the $1.197 billion National Dialysis Service Contract with VA Headquarters, which runs through September 2026 and carries the highest recompete risk at the next solicitation cycle.

DaVita operates almost exclusively as a prime contractor; sub-award activity appears negligible in the federal contracting footprint. The source identifies one grant sub-award: a DaVita Clinical Research sub-recipient award under Duke University's NIH-sponsored pragmatic clinical trial (August 2, 2024) for study closeout activities on a hemodialysis blood serum phosphate investigation, in which DaVita dieticians managed trial closure, data archival, and participant communications.

DaVita competes on an unrestricted, full-and-open basis across all recent awards — no set-aside designations (8(a), HUBZone, SDVOSB, WOSB, or other) are attached to any contract or IDV in the source data. This positions DaVita as a large business competing directly against other qualified dialysis providers in open federal procurement, leveraging its scale, subsidiary network, and established relationships with VA medical centers as competitive advantages rather than regulatory set-asides.